XML 74 R67.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Commitments and Contingencies - Additional Information (Detail) - USD ($)
$ in Thousands
 1 Months Ended 3 Months Ended
Oct. 30, 2023
Apr. 30, 2023
Feb. 28, 2023
Mar. 31, 2024
Mar. 31, 2023
Dec. 31, 2023
Commitments And Contingencies Disclosure [Line Items]            
CVR derivative liability       $ 4,780   $ 4,722
Purchase of property and equipment       231 $ 1,742  
Property and Equipment            
Commitments And Contingencies Disclosure [Line Items]            
Purchase of property and equipment       2,000    
Research and Development            
Commitments And Contingencies Disclosure [Line Items]            
Committed to allocate       $ 13,000    
Contingent Value Rights Agreement            
Commitments And Contingencies Disclosure [Line Items]            
Percentage of excess cash on dispositions net       100.00%    
Excess amount retained from net proceeds related to disposition of assets       $ 1,000    
Percentage of excess preapproved costs       100.00%    
Distribution to CVR holders from asset sale proceeds     $ 200      
Long-term CVR derivative liability     $ 4,500      
CVR derivative liability       $ 4,700    
Contributions closing payable amount $ 1,100          
Remaining outstanding balance       400    
Litigation expenses   $ 400        
F351 | Gyre Pharmaceuticals | Submission of the New Drug Application            
Commitments And Contingencies Disclosure [Line Items]            
Obligation to pay in exchange for the intellectual property rights       4,600    
F351 | Gyre Pharmaceuticals | NDA Passes the NMPA's Review and Inspection            
Commitments And Contingencies Disclosure [Line Items]            
Obligation to pay in exchange for the intellectual property rights       1,200    
F351 | Gyre Pharmaceuticals | NMPA's Approval of the NDA            
Commitments And Contingencies Disclosure [Line Items]            
Obligation to pay in exchange for the intellectual property rights       $ 7,000